PMID- 28474505
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20181114
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 5
IP  - 2
DP  - 2017 Jun
TI  - House dust mite-specific immunotherapy with two licensed vaccines: Outcome under 
      clinical routine conditions.
PG  - 132-140
LID - 10.1002/iid3.141 [doi]
AB  - INTRODUCTION: House dust mite (HDM) allergens are major causes for the 
      development of allergic diseases. A disease modifying effect and clinical benefit 
      of allergen immunotherapy (AIT) has been demonstrated in a number of clinical 
      trials. Clinical trials, however, are carried out in selected populations under 
      specific conditions based on inclusion and exclusion criteria and may not 
      represent the entire patient population from medical practice. Objective of this 
      study conducted in patients with HDM allergy was to systematically collect 
      information about the benefit of AIT under clinical routine conditions. METHODS: 
      In this prospective, multi-center non-interventional study, 220 patients (117 
      adults, 103 children) with HDM allergy receiving subcutaneous AIT with 
      Depigoid((R)) were monitored for 2 years. Organ-specific key symptoms, 
      health-related quality of life (QoL), and the use of concomitant anti-allergic 
      medication were assessed at baseline and after 12 and 24 months. Effectiveness 
      and tolerability of the AIT was assessed by physicians and patients. Occurrence 
      of adverse events (AEs) was continuously monitored. RESULTS: Two hundred and 
      nineteen patients (116 adults, 103 children) were evaluated. A major improvement 
      of the total symptom-score was observed after 24 (12) months in 76% (72%) and 80% 
      (79%) of adults and children, respectively, accompanied by a reduction in 
      concomitant anti-allergic medication and a pronounced improvement in QoL. The 
      effectiveness and tolerability of the AIT was estimated as very good/good by 
      80-90% of physicians and patients. AEs were observed in 4/117 adults (3.4%) and 
      in 7/103 children (6.8%). Serious AEs were reported in three adults and one 
      child: A grade-II anaphylactic reaction (one adult) controlled by oral 
      antihistamines (no hospitalization) classified as "definitely," three others as 
      not (2) or possibly (1) drug-related. CONCLUSIONS: The data collected from 220 
      patients confirm the efficacy, tolerability/safety, and acceptance of AIT with 
      Depigoid((R)) in adults and children with HDM allergy under routine clinical 
      conditions.
CI  - (c) 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & 
      Sons Ltd.
FAU - Mahler, Vera
AU  - Mahler V
AD  - Hautklinik Universitatsklinikum Erlangen, Erlangen, Germany.
FAU - Klein, Christian
AU  - Klein C
AD  - Novartis Pharma GmbH, Nurnberg, Germany.
FAU - Sager, Angelika
AU  - Sager A
AD  - LETI Pharma GmbH, Witten, Germany.
FAU - Zimmermann, Jurgen
AU  - Zimmermann J
AD  - Novartis Pharma GmbH, Nurnberg, Germany.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20170305
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Child
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Hypersensitivity/immunology/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Pyroglyphidae
MH  - Vaccines/*administration & dosage/immunology
PMC - PMC5418138
OTO - NOTNLM
OT  - Depigoid(R)
OT  - house dust mite
OT  - specific immunotherapy
EDAT- 2017/05/06 06:00
MHDA- 2018/11/15 06:00
PMCR- 2017/03/05
CRDT- 2017/05/06 06:00
PHST- 2016/06/09 00:00 [received]
PHST- 2016/10/31 00:00 [revised]
PHST- 2016/11/02 00:00 [accepted]
PHST- 2017/05/06 06:00 [entrez]
PHST- 2017/05/06 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2017/03/05 00:00 [pmc-release]
AID - IID3141 [pii]
AID - 10.1002/iid3.141 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2017 Jun;5(2):132-140. doi: 10.1002/iid3.141. Epub 2017 Mar 5.